Allergy Therapeutics looks forward to key hay fever trial


‘s () CFO Nick Wykeman and CEO Manuel Llobet join Proactive London’s Katie Pilbeam to discuss their record profits for the six-month stage, with revenues up 7% at GBP54mln for the half to December 31.

The group also posted pre-R&D operating income of GBP20.5mln, up 18.5%. The firm has highlighted top-line momentum and operational efficiency for the growth in profitability.

The operating margin advanced four percentage points to 38% year on year, while the cash balance was an impressive GBP48.3mln, or a net GBP44mln, up from GBP37mln 12 months earlier.


Please enter your comment!
Please enter your name here